Zhangshang Tangyi

The company's business strategy underwent a significant upgrade in 2017, expanding its service scope from solely diabetes to the broader chronic disease field and rebranding to "ClouDr Group" (智云健康). A pivotal moment in its growth was the successful listing on the Hong Kong Stock Exchange in July 2022, which solidified its position in the market. The firm primarily generates revenue by providing medical supplies and Software-as-a-Service (SaaS) products to hospitals and pharmacies, offering digital marketing services to pharmaceutical companies, and delivering online medical consultations and prescription services to patients.

Zhangshang Tangyi operates as a one-stop chronic disease management and smart medical platform, serving a wide array of clients including hospitals, pharmacies, pharmaceutical companies, patients, and doctors. Its core offerings are categorized into three main segments. The in-hospital solutions include medical supply distribution, a proprietary hospital SaaS system, and digital marketing services. For pharmacies, the company provides supplies and a dedicated pharmacy SaaS system. Its personal chronic disease management solutions encompass selling chronic disease-related products, membership services, and online platforms for doctor-patient communication, remote consultations, and prescription fulfillment with door-to-door medicine delivery. A key technological component is the self-developed AI platform, the ClouDr Medical Brain, which has evolved into two industry-specific large models, ClouD GPT and ClouD DTx, to aid in clinical decision support and medical research.